[PDF][PDF] Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
T Takano, Y Ohe, H Sakamoto, K Tsuta… - J Clin …, 2005 - mhlw-grants.niph.go.jp
Purpose To evaluate epidermal growth factor receptor (EGFH) mutations and copy number
as predictors of clinical outcome in patients with non-small-cell lung cancer (NSCLC) …
as predictors of clinical outcome in patients with non-small-cell lung cancer (NSCLC) …
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non–small-cell lung cancer with …
T Mitsudomi, T Kosaka, H Endoh, Y Horio… - Journal of Clinical …, 2005 - ascopubs.org
Purpose To evaluate the relationship between mutations of the epidermal growth factor
receptor (EGFR) gene and the effectiveness of gefitinib treatment in patients with recurrent …
receptor (EGFR) gene and the effectiveness of gefitinib treatment in patients with recurrent …
Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib
Purpose This study was undertaken to investigate the effects of epidermal growth factor
receptor (EGFR) mutation and its downstream signaling on response and survival in non …
receptor (EGFR) mutation and its downstream signaling on response and survival in non …
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non–small-cell lung cancer
F Cappuzzo, FR Hirsch, E Rossi… - Journal of the …, 2005 - academic.oup.com
Background: Gefitinib is a selective inhibitor of the epidermal growth factor (EGFR) tyrosine
kinase, which is overexpressed in many cancers, including non–small-cell lung cancer …
kinase, which is overexpressed in many cancers, including non–small-cell lung cancer …
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non–small cell …
TY Chou, CH Chiu, LH Li, CY Hsiao, CY Tzen… - Clinical cancer …, 2005 - AACR
Purpose: Mutations in epidermal growth factor receptor (EGFR) can be used to predict the
tumor response of patients receiving gefitinib for non–small cell lung cancer (NSCLC). We …
tumor response of patients receiving gefitinib for non–small cell lung cancer (NSCLC). We …
[HTML][HTML] Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer
Introduction: We evaluated the efficacy of gefitinib monotherapy prospectively in patients
with advanced or pretreated non-small cell lung cancer (NSCLC) harboring epidermal …
with advanced or pretreated non-small cell lung cancer (NSCLC) harboring epidermal …
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or …
DM Jackman, BY Yeap, LV Sequist, N Lindeman… - Clinical Cancer …, 2006 - AACR
Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …
Optimization of patient selection for gefitinib in non–small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt …
Purpose: Mutations in epidermal growth factor receptor (EGFR) are strongly predictive of
gefitinib efficacy in non–small-cell lung cancer. However, the presence of EGFR mutant …
gefitinib efficacy in non–small-cell lung cancer. However, the presence of EGFR mutant …
Clinical course of patients with non–small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
Purpose: In patients with non–small cell lung cancer (NSCLC), mutations in the epidermal
growth factor receptor (EGFR) tyrosine kinase domain have been associated with sensitivity …
growth factor receptor (EGFR) tyrosine kinase domain have been associated with sensitivity …
Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
JY Wu, SG Wu, CH Yang, CH Gow, YL Chang… - Clinical Cancer …, 2008 - AACR
Purpose: Clinical reports about responsiveness to gefitinib treatment in patients of non-small
cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor …
cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor …